Last reviewed · How we verify

NCT04530097

Radiofrequency Ablation Combined With Melatonin in the Treatment of Stage IA NSCLC

Status unknown NA Last updated 28 August 2020
What this trial tests

NA trial testing RFA in NSCLC and Theropy in 260 participants. Status unknown.

Timeline
1 January 2021
Primary endpoint
30 September 2022
30 September 2022

Quick facts

Lead sponsorShanghai 10th People's Hospital
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposetreatment
Enrollment260
Start date1 January 2021
Primary completion30 September 2022
Estimated completion30 September 2022
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Shanghai 10th People's Hospital

Who can join

Adults 18 to 85, any sex, with NSCLC and Theropy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Based on the recommendations of the guidelines, as well as the previous animal studies and clinical studies of our team, we designed and carried out prospective, randomized controlled, double-blind clinical studies to further expand the sample size to verify the efficacy of radiofrequency ablation combined with melatonin in the treatment of stage IA NSCLC. It is hoped that this combined treatment plan can delay the recurrence of lung cancer after RFA and prolong the survival time of patients.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Systematic and comprehensive insights into HIF-1 stabilization under normoxic conditions: implications for cellular adaptation and therapeutic strategies in cancer.
    Zhang J, Yao M, Xia S, Zeng F, et al · · 2025 · cited 63× · PMID 39757165 · DOI 10.1186/s11658-024-00682-7

Verify or expand the search:

Other trials of RFA

Trials testing the same drug.

Other Shanghai 10th People's Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04530097.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing